10:58 AM EDT, 07/03/2025 (MT Newswires) -- (Updates with AstraZeneca's ( AZN ) response in the second paragraph.)

AstraZeneca ( AZN ) is in talks with Summit Therapeutics ( SMMT ) on a partnership deal in which it could pay as much as $15 billion over time to license a drug to treat lung cancer, Bloomberg reported, citing people familiar with the matter.

AstraZeneca ( AZN ) declined to comment when reached by MT Newswires while Summit did not immediately reply to a request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 69.91, Change: -1.22, Percent Change: -1.72